https://www.prognyx.com/blog/carvykti-half-of-early-line-myeloma-patients-in-five-year-treatment-free-remissiPrognyxen2026-09-26Carvykti: half of early-line myeloma patients in five-year treatment-free remission https://www.prognyx.com/blog/per-endpoints-merck-s-welireg-lenvima-wins-fda-approval-in-advanced-ccrccPrognyxen2026-09-25Per Endpoints, Merck's Welireg-Lenvima wins FDA approval in advanced ccRCC